Peter Thiel-backed ATAI launches new Salvia-focused biotech; Purdue bankruptcy trial expected to begin today — report
ATAI Life Sciences, the Peter Thiel-backed umbrella developer of psychedelics and other drugs for mental health conditions, launched a new portfolio company Thursday.
The new outfit is called Revixia Life Sciences, and its mission is to bring the main active ingredient in Salvia to the clinic for treatment-resistant depression, substance use disorder and pain, ATAI announced Thursday morning. The ingredient in question is called Salvinorin A, and Revixia says it’s a non-nitrogenous agonist of the kappa-opioid receptor.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.